Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2025)

Caribou Biosciences has reported Non-Current Assets over the past 6 years, most recently at $30.1 million for Q4 2025.

  • Quarterly Non-Current Assets fell 67.92% to $30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $154.3 million through Dec 2025, down 61.91% year-over-year, with the annual reading at $30.1 million for FY2025, 67.92% down from the prior year.
  • Non-Current Assets was $30.1 million for Q4 2025 at Caribou Biosciences, down from $39.5 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $113.5 million in Q4 2022 and troughed at $12.9 million in Q3 2021.
  • The 5-year median for Non-Current Assets is $81.1 million (2023), against an average of $72.6 million.
  • Year-over-year, Non-Current Assets skyrocketed 611.69% in 2022 and then tumbled 72.18% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $51.2 million in 2021, then soared by 121.87% to $113.5 million in 2022, then fell by 17.75% to $93.4 million in 2023, then increased by 0.61% to $93.9 million in 2024, then plummeted by 67.92% to $30.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non-Current Assets are $30.1 million (Q4 2025), $39.5 million (Q3 2025), and $28.4 million (Q2 2025).